Logos Global Management LP Portfolio
Auto-discovered 13F filer (Top-2000 by latest reported value).
SEC 13F CIK: 0001792126
What is a 13F filing? Who files one and when · What 13F filings can't tell you
Q4 2024 · 47 positions · Total reported value $854.65M · Top-10 concentration 52.1% · Updated 2026-10-18
Last updated: 2026-10-18 · Source: SEC EDGAR Form 13F-HR
Turnover: 72.7% · 25 new · 19 cut · 20 exited
Active Share (vs S&P 500): 100.0% · vs QQQ: 100.0% — share of the book that differs from index weights (higher = more active) · ranking
Est. Qtr Return (Q1 2026 → Q2 2026): +22.9% · vs SPY +8.1% · Prev Value $1.89B — last quarter positions weighted by this quarter price moves · ranking
In its Q4 2024 13F filing, Logos Global Management LP disclosed 47 equity positions with a combined reported value of $854.65M. The filing implies a moderately concentrated portfolio: its ten largest positions account for 52.1% of reported value. HoldingsHub classifies the profile as Small / Health Tilt / High Turnover.
The largest disclosed positions as of Q4 2024 were IDYA ($77.10M), JANX ($66.92M), RVMD ($63.42M). By sector, the heaviest allocations are Health Care 83.9%, Other 16.1%. Versus the prior quarter, allocation shifted toward Other (+1.8pp) and away from Health Care (-1.8pp).
Versus the prior quarter, Logos Global Management LP opened 25 new positions, trimmed 19 and fully exited 20, a turnover rate of 72.7% of positions. The portfolio's overlap with the prior quarter was 44% of names.
The largest new positions opened in Q4 2024 were BNTX ($34.19M), INSM ($31.07M), NBIX ($27.30M).
Of the 20 positions fully exited versus the prior quarter, the largest were CLDX ($30.59M), IONS ($30.05M), LKFT ($23.03M).
Figures come from the fund's SEC Form 13F filing. 13F reports are filed within 45 days of quarter end and cover long positions of $100,000 or more; they exclude short positions and non-13F asset classes, so treat this page as a quarter-end snapshot rather than the fund's live book.
New Positions (Q4 2024)
- BNTX BIONTECH SE · $34.19M
- INSM INSMED INC · $31.07M
- NBIX NEUROCRINE BIOSCIENCES INC · $27.30M
- JAZZ JAZZ PHARMACEUTICALS PLC · $21.55M
- BPMC BLUEPRINT MEDICINES CORP · $17.44M
- SLNO SOLENO THERAPEUTICS INC · $15.73M
- ALKS ALKERMES PLC · $14.38M
- APGE APOGEE THERAPEUTICS INC · $13.59M
Fully Exited (vs previous quarter)
- CLDX CELLDEX THERAPEUTICS INC NEW · prev qtr: $30.59M · history
- IONS IONIS PHARMACEUTICALS INC · prev qtr: $30.05M
- LKFT LAKEFRONT BIOTHERAPEUTICS NV · prev qtr: $23.03M
- COGT COGENT BIOSCIENCES INC · prev qtr: $21.60M · history
- BCAX BICARA THERAPEUTICS INC · prev qtr: $20.38M
- SRPT SAREPTA THERAPEUTICS INC · prev qtr: $18.73M
- BEAM BEAM THERAPEUTICS INC · prev qtr: $12.25M
- BCYC BICYCLE THERAPEUTICS PLC · prev qtr: $11.31M
Insider Transactions (Form 4)
Latest Logos Global Management LP buys and sells reported on SEC Form 4 — filed within two business days when the fund's ownership in a stock crosses 10%.
No Form 4 filings for this fund yet — when its ownership in a stock crosses 10%, buys and sells are filed here within two business days.
Fund Profile
Logos Global Management LP is an SEC-registered 13F filer based in San Francisco, CA, United States. As of Q2 2026 it reported 68 US equity positions with a combined value of $2.32B. HoldingsHub carries 12 quarters of its filings (Q3 2023–Q2 2026).
Firm Snapshot
- Headquarters: SAN FRANCISCO, CA, United States
- SEC registration: 801-117248 (status: Approved), registered 2019-08-26
- Regulatory AUM (Form ADV): $2.25B as of 2026-04-22
- Client mix (by RAUM): pension and profit-sharing plans 100%
- Manages 5 private funds, of which 1 hedge funds
Portfolio Structure
- 68 positions · $2.32B reported value (Q2 2026)
- Top 10 holdings = 48.3% of reported value
- Largest position: ERAS (ERASCA INC COM) at 9.6%
- Average position size: $34.16M
Sector Tilt
- Health Care 99.1%
- Financials 0.1%
- (classified holdings cover 99% of value)
Quarterly Activity
- Q2 2026: 25 new, 18 added, 19 reduced, 20 exited
- 6 positions unchanged
Generated from the firm's public SEC Form 13F and ADV filings. It states what the firm has reported — not an evaluation of its strategy, and not investment advice.
| # | Company | Shares | Value | Weight | Allocation | Change |
|---|---|---|---|---|---|---|
| 1 |
|
3.00M | $77.10M | 9.02% | Add | |
| 2 |
|
1.25M | $66.92M | 7.83% | Add | |
| 3 |
|
1.45M | $63.42M | 7.42% | Add | |
| 4 |
|
900.00K | $42.34M | 4.95% | Add | |
| 5 |
|
875.00K | $37.00M | 4.33% | Add | |
| 6 |
|
300.00K | $34.19M | 4.00% | New | |
| 7 |
|
750.00K | $31.54M | 3.69% | Add | |
| 8 |
|
12.50M | $31.38M | 3.67% | Add | |
| 9 |
|
450.00K | $31.07M | 3.63% | New | |
| 10 |
|
3.50M | $29.89M | 3.50% | Hold | |
| 11 |
|
200.00K | $27.30M | 3.19% | New | |
| 12 |
|
4.22M | $26.02M | 3.04% | Hold | |
| 13 |
|
300.00K | $24.56M | 2.87% | Hold | |
| 14 |
|
800.00K | $22.26M | 2.60% | Hold | |
| 15 |
|
175.00K | $21.55M | 2.52% | New | |
| 16 |
|
700.00K | $18.98M | 2.22% | Reduce | |
| 17 |
|
3.21M | $18.71M | 2.19% | Hold | |
| 18 |
|
200.00K | $17.44M | 2.04% | New | |
| 19 |
|
1.00M | $17.42M | 2.04% | Reduce | |
| 20 |
|
500.00K | $15.96M | 1.87% | Reduce | |
| 21 |
|
350.00K | $15.73M | 1.84% | New | |
| 22 |
|
500.00K | $14.38M | 1.68% | New | |
| 23 |
|
300.00K | $13.59M | 1.59% | New | |
| 24 |
|
700.00K | $13.42M | 1.57% | Add | |
| 25 |
|
2.55M | $13.08M | 1.53% | Reduce | |
| 26 |
|
200.00K | $12.68M | 1.48% | Reduce | |
| 27 |
|
500.00K | $11.64M | 1.36% | Add | |
| 28 |
|
400.00K | $10.68M | 1.25% | Reduce | |
| 29 |
|
450.00K | $10.60M | 1.24% | Add | |
| 30 |
|
750.00K | $9.88M | 1.16% | New | |
| 31 |
|
245.00K | $8.82M | 1.03% | New | |
| 32 |
|
1.00M | $7.83M | 0.92% | Add | |
| 33 |
|
300.00K | $7.43M | 0.87% | Reduce | |
| 34 |
|
2.00M | $7.08M | 0.83% | New | |
| 35 |
|
2.22M | $5.51M | 0.65% | New | |
| 36 |
|
1.25M | $5.15M | 0.60% | Reduce | |
| 37 |
|
500.00K | $4.47M | 0.52% | Hold | |
| 38 |
|
5.08M | $4.03M | 0.47% | Hold | |
| 39 |
|
1.40M | $3.71M | 0.43% | New | |
| 40 |
|
208.91K | $3.71M | 0.43% | Hold | |
| 41 |
|
1.00M | $3.62M | 0.42% | Reduce | |
| 42 |
|
2.90M | $3.51M | 0.41% | Hold | |
| 43 |
|
140.00K | $3.15M | 0.37% | Reduce | |
| 44 |
|
134.20K | $3.07M | 0.36% | New | |
| 45 |
|
145.09K | $1.46M | 0.17% | Hold | |
| 46 |
|
5.40M | $1.34M | 0.16% | New | |
| 47 |
|
66.67K | $15.33K | 0.00% | New | |
FAQ
What did Logos Global Management LP buy in 2024-Q4?
In its 2024-Q4 13F filing, Logos Global Management LP reported 47 equity positions worth $854.65M in aggregate; its largest disclosed positions were IDYA ($77.10M), JANX ($66.92M), RVMD ($63.42M).
How large is Logos Global Management LP's portfolio?
Logos Global Management LP reported $854.65M of long equity holdings across 47 positions as of 2024-Q4. Top-10 holdings account for 52.1% of reported value.
What is Logos Global Management LP's investment style?
HoldingsHub classifies the portfolio as Small / Health Tilt / High Turnover, computed from size, concentration, sector tilt and turnover.
Where does this data come from?
All figures are computed from the fund's SEC Form 13F quarterly filing, which must be filed within 45 days of quarter end for long positions of $100,000 or more.